- Ongoing, recruitingTherapeutic confirmatory (Phase III)
TRIANGLE - autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European mcl network trial
This study looks at new ways to treat a type of cancer called mantle cell lymphoma. It compares standard treatment with a new approach using the drug ibrutinib, to see if it helps patients live longer without their cancer getting worse.
For: Generalized mantle cell LymphomaNorway · Spain · Poland - RecruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Mantle Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study is looking at two different medicine combinations for people with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). We want to see if a newer treatment works better at stopping the cancer from growing.
For: Leukemia, Lymphocytic, Chronic, B-CellUnited States · Belgium · Canada - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study compares a new medicine, pirtobrutinib, with ibrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's for adults, some of whom may have had previous treatment, and some who are newly diagnosed, especially if they have a specific gene change.
For: Chronic Lymphocytic Leukemia · Leukemia, Lymphocytic · Leukemia, B-cellUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This study compares a new drug, pirtobrutinib, with existing approved treatments for people with a type of blood cancer called mantle cell lymphoma (MCL). It's for patients who have already had at least one treatment and are looking for other options.
For: Lymphoma, Mantle-CellUnited States · Australia · Austria - Active not recruitingPHASE2
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction
This study looks at combining two drugs, ibrutinib and daratumumab, for people with chronic lymphocytic leukemia (CLL) that has come back or not responded well to past treatments. It focuses on patients whose cancer has specific genetic changes, aiming to see if this combination works better.
For: Relapsed or Refractory Chronic Lymphocytic LeukemiaFrance - Active not recruitingPHASE4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
This study helps people with certain cancers or GvHD who are already taking ibrutinib and benefiting from it. It allows them to keep getting the medication if they can't get it commercially and helps researchers learn more about its long-term use.
For: Lymphoma, B-Cell · Lymphoma, Non-Hodgkin · Leukemia, B-cellUnited States · Australia · Canada - Active not recruitingPHASE1, PHASE2
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This study is testing a new cell therapy called rapcabtagene autoleucel for different types of blood cancers, including certain lymphomas and leukaemias. It aims to see if the treatment is safe, works well, and how best to give it, sometimes with another drug called ibrutinib.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Diffuse Large B-cell LymphomaUnited States · Australia · Austria - RecruitingPHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
This study looks at a new drug, epcoritamab, combined with other cancer medicines, for adults with Non-Hodgkin Lymphoma. It aims to see how safe these combinations are and if they help reduce the disease. Epcoritamab is given as an injection under the skin.
For: Non-Hodgkin LymphomaUnited States · China · Czechia - RecruitingPHASE2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
This study looks at adding a new drug, ibrutinib, to usual treatment for a type of brain lymphoma called PCNSL. It aims to see if this combination can better stop the cancer from growing or spreading in people who can't have a stem cell transplant.
For: Non-hodgkin LymphomaCanada - Active not recruitingPHASE2
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
This study looks at combining two drugs, Carfilzomib and Ibrutinib, to treat Waldenström's Macroglobulinemia (WM). We want to see if this combination works better than Ibrutinib alone, especially for patients whose disease has certain genetic features. It's a Phase 2 trial.
For: Waldenstrom MacroglobulinemiaAustria · Germany · Greece - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
This study compares two medicines, Acalabrutinib and Ibrutinib, for people in the UK with a type of blood cancer called Chronic Lymphocytic Leukemia (CLL) that has been treated before. It wants to see which medicine works better at stopping the cancer from getting worse.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Belgium